Overview

* DiaMedica Q3 net loss and EPS missed analyst expectations

* Cash and investments increased to $55 mln, providing runway into 2H 2027

Outlook

* Company anticipates cash runway into 2H 2027

Result Drivers

* R&D EXPENSES - Increased due to progress in ReMEDy2 trial and Phase 2 IST in preeclampsia

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS Miss -$0.17 -$0.16

(3

Analysts

)

Q3 Net Miss -$8.62 -$8.13

Income mln mln (3

Analysts

)

Q3 Miss -$9.03 -$8.33

Operatin mln mln (3

g Income Analysts

)

Q3 Cash $55.30

& mln

Investme

nts

Q3 -$8.61

Pretax mln

Profit

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for DiaMedica Therapeutics Inc ( DMAC ) is $12.00, about 46.8% above its November 11 closing price of $6.39

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)